Frazier Life Sciences Amends 13D Filing for NewAmsterdam Pharma

TL;DR

Frazier Life Sciences X, L.P. updated their stake in NewAmsterdam Pharma Co N.V. on 12/17/24.

AI Summary

Frazier Life Sciences X, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of NewAmsterdam Pharma Co N.V. as of December 17, 2024. The filing details the group members involved in this reporting entity, including various Frazier Life Sciences funds and individuals like Albert Cha and Daniel Estes.

Why It Matters

This filing indicates a potential shift in significant shareholding or strategic interest in NewAmsterdam Pharma Co N.V. by a major life sciences investment firm.

Risk Assessment

Risk Level: medium — Schedule 13D filings often signal significant investor activity, which can lead to volatility or strategic changes in the target company.

Key Players & Entities

• Frazier Life Sciences X, L.P. (company) — Reporting entity
• NewAmsterdam Pharma Co N.V. (company) — Subject company
• Albert Cha (person) — Group member
• Daniel Estes (person) — Group member
• Frazier Life Sciences Public Fund, L.P. (company) — Group member

FAQ

Filing Documents

• d507124dsc13da.htm (SC 13D/A) — 325KB
• 0001193125-24-280208.txt ( ) — 328KB

From the Filing

SC 13D/A 1 d507124dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON , D.C. 20549 SCHEDULE 13D U NDER T HE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. 4)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N62509 109 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 13, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. N62509 109 1. Name of Reporting Persons. Frazier Lifesciences Sponsor LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 3,968,000 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 3,968,000 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 3,968,000 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 3.7% (2) 14. Type of Reporting Person (See Instructions) OO (1) Consists of (i) 3,801,000 Ordinary Shares held directly by Frazier Lifesciences Sponsor LLC and (ii) 167,000 Ordinary Shares that are issuable upon the exercise of warrants held directly by Frazier Lifesciences Sponsor LLC that are exercisable within 60 days of December 13, 2024. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Lifesciences Sponsor LLC. (2) Based on (i) 92,385,872 Ordinary Shares that were outstanding on October 31, 2024 as set forth in the Issuers Form 10-Q as filed with the SEC on November 6, 2024, (ii) 14,667,347 Ordinary Shares that were sold by the Issuer in connection with its public offering as described in the Issuers final prospectus filed with the SEC pursuant to Rule 424(b)(5) on December 13, 2024, and (iii) 167,000 Ordinary Shares that are issuable upon the exercise of warrants held directly by Frazier Lifesciences Sponsor LLC that are exercisable within 60 days of December 13, 2024. Page 2 CUSIP No. N62509 109 1. Name of Reporting Persons. Frazier Life Sciences X, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 7,309,762 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 7,309,762 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 7,309,762 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 6.8% (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of (i) 3,801,000 Ordinary Shares held directly by Frazier Lifesciences Sponsor LLC, (ii) 167,000 Ordinary Shares that are issuable upon the exercise of warrants held directly

View Full Filing

View this SC 13D/A filing on SEC EDGAR